TF 002
Phase 2Small molecule
TF 002 is one of 6 small molecule programs targeting Mastocytosis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Mastocytosis
#DrugCompanyPhaseTrials
1Rydapt
NovartisApproved
Plaquenil
Alnylam PharmaceuticalsApproved
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Masitinib
AAB Science
Phase 2
Cromoglicate
LEO PharmaPhase 2
TF 002
JJADO Technologies GmbH
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TF 002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJADO Technologies GmbH